51 unknown. 51 Phase 1, 24 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 51 | Unknown 51 |
| Phase 2 | 24 | Unknown 24 |
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer HRS-9815 injection - Prostate Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 9 | 2023-10-01 | 2023-10-02 |
| Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Sinotau Pharmaceutical Group | 32 | 2023-09-13 | 2024-05-03 |
| Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer QLH12016 - Prostate Cancer | Phase 1 | Unknown | Qilu Pharmaceutical Co., Ltd. | 108 | 2023-08-31 | 2023-08-02 |
| Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg Goserelin Acetate Sustained-Release Microspheres for Injection, Zoladex 10.8 MG Drug Implant - Prostate Cancer | Phase 1 | Unknown | Luye Pharma Group Ltd. | 24 | 2023-05-01 | 2023-05-12 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NGM438, Pembrolizumab (KEYTRUDA ®) - Pancreatic Cancer, Breast Cancer | Phase 1 | Unknown | NGM Biopharmaceuticals, Inc | 71 | 2022-05-11 | 2024-04-01 |
| 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer 64Cu-SAR-bisPSMA - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Luke Nordquist, MD | 150 | 2022-03-28 | 2022-03-18 |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients Abiraterone Acetate - Prostate Cancer, Metastatic Cancer | Phase 1 | Unknown | National University Hospital, Singapore | 10 | 2021-11-30 | 2024-01-08 |
| A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Exercise - Exercise, Prostate Cancer | Phase 1 / Phase 2 | Unknown | Kira Murphy | 24 | 2021-09-09 | 2021-12-14 |
| MDPK67b in Patients With Prostate Cancer MDPK67b - Prostate Cancer | Phase 1 | Unknown | Med Discovery SA | 15 | 2021-08-09 | 2023-11-07 |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors EU101 - Solid Tumor, Renal Cell Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Eutilex | 110 | 2021-05-31 | 2024-03-15 |
| To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers leuprorelin acetate 3.75mg - Prostate Cancer | Phase 1 | Unknown | Peptron, Inc. | 40 | 2021-03-11 | 2021-03-17 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients Radio guided surgery (RGS) using Indium-labelled PSMA - Prostate Cancer, Lymph Node Metastases | Phase 1 / Phase 2 | Unknown | Radboud University Medical Center | 20 | 2020-09-01 | 2022-04-29 |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell - Colorectal Cancer, Triple Negative Breast Cancer | Phase 1 | Unknown | CytoMed Therapeutics Pte Ltd | 10 | 2019-12-01 | 2019-09-27 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour MRx0518 Capsules, MRx0518/placebo Capsules - Melanoma, Breast Cancer | Phase 1 | Unknown | Imperial College London | 120 | 2019-04-10 | 2022-08-11 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms Palbociclib, Rivaroxaban, SNP - Cancer, Solid Tumor | Phase 1 | Unknown | Lebanese University | 500 | 2019-02-01 | 2023-10-06 |
| PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer autologous T cells & cyclophosphamide - Prostate Cancer | Phase 1 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 12 | 2018-08-02 | 2023-11-29 |
| A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer 18F-AlF-NOTA-neurotensin - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Xiangya Hospital of Central South University | 65 | 2018-04-23 | 2018-05-17 |
| Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment Therapeutic vaccine, PD-1 Knockout T Cells - Prostate Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Guangdong Pharmaceutical University | 30 | 2018-02-22 | 2018-05-16 |
| Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Evofosfamide, Ipilimumab - Pancreatic Cancer, Melanoma | Phase 1 | Unknown | Threshold Pharmaceuticals | 69 | 2017-05-10 | 2017-10-30 |
Showing 20 of 51. Sign in to see all of them.
Prostatic Neoplasms (51) · Neoplasms (7) · Breast Neoplasms (5) · Pancreatic Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Colonic Neoplasms (3) · Lung Neoplasms (3) · Melanoma (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Adenoviridae Infections (2)
Genital Diseases (51) · Male Urogenital Diseases (51) · Urogenital Diseases (51) · Genital Diseases, Male (50) · Genital Neoplasms, Male (50) · Neoplasms by Site (50) · Urogenital Neoplasms (50) · Prostatic Diseases (49) · Neoplasms (44) · Neoplasms by Histologic Type (9) · Carcinoma (8) · Neoplasms, Glandular and Epithelial (8) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Pathological Conditions, Signs and Symptoms (7)
Abiraterone Acetate (2) · Docetaxel (2) · Estramustine (2) · Filgrastim (2) · Leuprolide (2) · Mitoxantrone (2) · Radiotherapy, Intensity-Modulated (2) · pembrolizumab (2) · 68Ga-NOTA-RM26 (1) · Amantadine (1) · Brachytherapy (1) · Cyclophosphamide (1) · Cyclosporine (1) · Drug Implants (1) · Exercise (1)
Herbert Irving Comprehensive Cancer Center (2) · Jonsson Comprehensive Cancer Center (2) · Sunnybrook Health Sciences Centre (2) · AHS Cancer Control Alberta (1) · Adamis Pharmaceuticals Corporation (1) · Arno Therapeutics (1) · Biotech Equity Partners Pty Ltd (1) · Carisma Therapeutics Inc (1) · Center for Molecular Medicine (1) · CytoMed Therapeutics Pte Ltd (1) · Daewoong Pharmaceutical Co. LTD. (1) · Eutilex (1) · First Affiliated Hospital of Chengdu Medical College (1) · Hope Cancer Institute, Inc. (1) · Imperial College London (1)
United States (16) · China (9) · Canada (4) · United Kingdom (4) · Netherlands (2) · Australia (1) · Ireland (1) · Israel (1) · Italy (1) · Japan (1) · Lebanon (1) · Malaysia (1) · Norway (1) · Russia (1) · Singapore (1)
Daniel P. Petrylak, MD (2) · Andrew Loblaw, MD (1) · Andrew Loblaw, MD, FRCPC (1) · Arie Belldegrun, MD, FACS (1) · Bernard Fox, PhD (1) · Carol M. Richman, MD (1) · Daniel Eberli, Prof. (1) · David Hong, MD (1) · David N Dalley, MB BS FRACP (1) · David P. Dearnaley, MD, FRCP, FRCR (1) · Dingwei Ye (1) · Dr Jonathan Krell (1) · Edmund Chiong, MBBS, PhD (1) · Elisabeth I Heath, MD (1) · Giorgio Guazzoni, MD (1)
PMID 23522299, PMID 28498618, PMID 36441083, PMID 38172595, PMID 38176721, PMID 38997466, PMID 39095735, PMID 39726590, PMID 39920391, PMID 40540036
2019 (1), M01RR000030 (1), ZIAEB000073 (1)